Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
about
A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory DiseasesTumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterLarge-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review.Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data.Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterPain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study.Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingThe role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agentsEconomic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.Predictors for clinical outcome in psoriatic arthritis - what have we learned from cohort studies?Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.Treatment of psoriasis with etanercept: the typical patient profile.Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.Predictors of long-term drug survival for infliximab in psoriasis.Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data.Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.Differential Drug Survival of Second-Line Biologic Therapies In Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis.Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.
P2860
Q26778585-2FF5EA11-FC5F-4687-8A7C-5163E1653CC9Q27012134-7DFC17D0-7989-4919-A423-0EF38586E161Q30399745-CB701AAF-DD5D-4CC5-95C6-277F35658839Q30612910-13E738DB-51F3-4571-AF1A-CF45BE7AE151Q33726924-9C7112AD-F1EF-4CC9-BDEA-BB26581C7B3DQ33858767-B84F4CB4-849D-4696-A45A-72C2B2400A47Q33993099-41A16620-1EFB-4FCF-A4D3-50BE6968BB38Q34017619-3C37A2AC-480F-4284-919F-D59CA304217BQ34109394-CEC72DFC-ABA5-45D8-BAFA-6693C63E2B4EQ34623922-6A372C3D-3863-4299-A9D9-0B8D05AC5ED6Q36819032-01810827-0037-4C64-842F-F70D3A91ACDBQ37221862-6742A09A-EE78-4657-BDBC-20B22AC9C8F2Q37301134-6D5FFA9B-A43B-4E38-906C-4642BB236BB7Q37453027-371E2E5A-918B-46A9-993D-5DD3D4008C4BQ37826195-457EB028-98F0-4AE3-9968-9AE3751C8409Q37865413-96358DEB-A565-46E7-8803-6FD08111D165Q37980484-47DEE1A6-B42E-49F5-A3CC-101A9F918D9AQ38035726-BE8B6663-1821-4D12-9F32-92AE94E838D9Q38202212-BA5A9EB4-1241-40FC-B9FB-045C91F93418Q38204241-F995420F-EAA5-42AB-9880-EA923411F544Q38207759-6B9FF2EA-B293-439A-A4C2-5BD63951972FQ38238931-ACB331D1-17BC-4776-89DB-7E64E824A2E7Q38264660-063C1D97-DCC9-44E3-97ED-F4AE6BAD8D84Q38668527-A74E7CA0-4163-4E81-8970-8AD82E99B4B6Q38807058-671C3F17-121B-4E45-8768-553B54189C98Q38883385-5309A242-21DD-4E8B-AD31-16995B278469Q39668241-D847F1E2-8F37-4637-AE6A-F038817B7248Q40261663-C669C300-6E1F-44F9-A8B5-00C560A87250Q40556448-6A3325D9-A760-4773-BB6C-D4A2468E67BBQ42210089-0B02B35C-9754-4935-867B-42B8CC3DB907Q42560566-81714C9E-18ED-4D7B-92C0-14BDD158F7E2Q43991141-5BCC1CEA-7D91-487B-843E-1BDBFF18F20AQ44564160-A77381B6-46A1-4A75-B177-D2735E36C836Q46893265-84F735CD-7627-46B1-A871-9F35B2572C3BQ47114261-4CFF8D62-C599-465A-B361-E2809D7D6CACQ47595036-FB3D6675-E335-464E-AFAB-B889E365A256Q47595988-30A1657F-4CA6-4879-BFDB-7552610B7CB8Q47943997-40988A1D-01BD-4016-8CE6-A2CE662F1410Q50220930-0A222321-8001-4CF5-9CBC-08697147C395Q50553120-AA3C7646-FF35-49EF-8001-2688F84BB762
P2860
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Persistence with anti-tumour n ...... heumatology Biologics Register
@en
Persistence with anti-tumour n ...... eumatology Biologics Register.
@nl
type
label
Persistence with anti-tumour n ...... heumatology Biologics Register
@en
Persistence with anti-tumour n ...... eumatology Biologics Register.
@nl
prefLabel
Persistence with anti-tumour n ...... heumatology Biologics Register
@en
Persistence with anti-tumour n ...... eumatology Biologics Register.
@nl
P2093
P2860
P356
P1476
Persistence with anti-tumour n ...... heumatology Biologics Register
@en
P2093
Amr A Saad
British Society for Rheumatology Biologics Register
Deborah P M Symmons
Kath D Watson
Kimme L Hyrich
Peter R Noyce
P2860
P2888
P356
10.1186/AR2670
P577
2009-04-08T00:00:00Z
P5875
P6179
1020428573